Comparative Study of Intravenous Iron versus Intravenous Ascorbic Acid for Treatment of Functional Iron Deficiency in Hemodialysis Patients
Phase 2
- Conditions
- Condition 1: Hemodialysis. Condition 2: Iron deficiency anaemia.Extracorporeal dialysisIron deficiency anaemia, unspecified
- Registration Number
- IRCT201112248501N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1) Ferritin level = 500ng/ml and TSAT= 25%; 2) Hemodialysis therapy for = 3 months; 3) Duration of recombinant human Erythropoietin (rHYEPO) treatment = 6 months at lest 6000 u/week; 4)Hemoglobin level < 11 gr/dl and Stable hemoglobin levels for four consecutive weeks; 5)The Hemodialysis patients= 18 years and<70 years. Exclusion criteria: 1) Blood transfusion during 3 months ago; 2) Blood loss during 3 months ago; 3) Acute infection; 4) Chronic inflammatory disease; 5) Active liver disease; 6) Hemoglobinopathy such as sickle cell disease; 7) Adminstration of intravenous Iron during 3 months ago.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin. Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: computerized coulter counter(Abbot Machine made in USA).
- Secondary Outcome Measures
Name Time Method Sreum Ferritin. Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In ng/ml and will measure by LIAZON kit(made in Italy).;Serum Iron. Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In ng/ml and will measure by Pars Azmoon kit (made in Iran) and Hitachi analyzer (Model 911, made in Japan).;Total Iron Binding Capacity(TIBC). Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In mg/dl and will measure by Pars Azmoon kit(made in Iran) and Hitachi analyzer (Model 911, made in Japan).;Transferrin Saturation(TSAT). Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In Percent and will calculate by dividing serum Iron by TIBC x 100.